Last reviewed · How we verify
Ramipril (ACE-inhibitor)
Ramipril inhibits angiotensin-converting enzyme (ACE), reducing the conversion of angiotensin I to angiotensin II and thereby lowering blood pressure and reducing cardiac workload.
Ramipril inhibits angiotensin-converting enzyme (ACE), reducing the conversion of angiotensin I to angiotensin II and thereby lowering blood pressure and reducing cardiac workload. Used for Hypertension, Heart failure, Post-myocardial infarction.
At a glance
| Generic name | Ramipril (ACE-inhibitor) |
|---|---|
| Also known as | Ramipril |
| Sponsor | National Heart Institute, Egypt |
| Drug class | ACE inhibitor |
| Target | Angiotensin-converting enzyme (ACE) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
ACE inhibitors block the enzyme responsible for producing angiotensin II, a potent vasoconstrictor. By reducing angiotensin II levels, ramipril causes vasodilation, decreases peripheral vascular resistance, and reduces aldosterone secretion, leading to lower blood pressure and improved cardiac function. This mechanism also provides cardioprotective and renoprotective effects.
Approved indications
- Hypertension
- Heart failure
- Post-myocardial infarction
- Diabetic nephropathy prevention
Common side effects
- Dry cough
- Dizziness
- Fatigue
- Hyperkalemia
- Angioedema
- Headache
Key clinical trials
- Short-Term Effects of Antihypertensive Drugs on Postural Balance and Fall Risk (NA)
- The COVID-RASi Trial (COVID-19) (PHASE3)
- Pentoxifylline on Inflammatory Markers in Non-Diabetic Chronic Kidney Disease Patients (NA)
- Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants (PHASE4)
- Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure (PHASE4)
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE) (NA)
- Effect of Continuing vs. Discontinuing ACE Inhibitors on Renal Function After Coronary Angiography (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ramipril (ACE-inhibitor) CI brief — competitive landscape report
- Ramipril (ACE-inhibitor) updates RSS · CI watch RSS
- National Heart Institute, Egypt portfolio CI